Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (8125)	5/23/2005 9:59:33 PM
From: Galirayo	Respond to of 23958

Sergio, Yes .. from the weekly it looks like a Roller. stockcharts.com[w,a]wacayiay[dd][pb20!c8!f][vc60][iut!Ua12,26,9!Uv25]&pref=G The Folio was at 40 .. I weeded it some today. Ray

To: Sergio H who wrote (8125)	5/24/2005 9:02:33 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[OWENQ] Should Rock today.... along with the other Asbestos ones. I flipped it to a Long yesterday afternoon. :) finance.yahoo.com This one's up 8 to 9%. finance.yahoo.com

To: Sergio H who wrote (8125)	5/24/2005 10:08:13 AM
From: Galirayo	Respond to of 23958

[EYET] I added it on the Slide. EYETECH PHARMA (NasdaqNM:EYET) Delayed quote data Last Trade: 13.97 Trade Time: 9:51AM ET Change: 10.00 (41.72%) biz.yahoo.com MarketWatch Market Pulse: Eyetech's Macugen gets approval in Brazil Tuesday May 24, 7:49 am ET By Michael Baron NEW YORK (MarketWatch) -- Eyetech Pharmaceuticals said Tuesday that its Macugen treatment for wet age-related macular degeneration has received marketing approval in Brazil. The news came as Eyetech's stock plummeted 36.4% to $15.25 on Instinet following news of positive trial results for a rival treatment being developed by Genentech .